

Gregory J. Gailius Joins Advantagene Board of Directors as Chairman of Audit Committee

Auburndale, MA, January 25, 2017 - Advantagene, Inc., a clinical-stage biotechnology company developing a novel cancer immunotherapy platform for the treatment of solid tumors, announced today that Gregory J. Gailius, C.P.A., has joined the company's Board of Directors and will serve as Chairman of the Audit Committee. Mr. Gailius recently retired as a partner in the transaction service/deals practice of *PricewaterhouseCoopers (PwC)*.

"We are very pleased to welcome Greg to the Advantagene Board of Directors," said Dr. Estuardo Aguilar-Cordova, Chairman and Chief Executive Officer of Advantagene. "Greg's deal making, corporate finance and accounting expertise make him an ideal board member and Chairman of the Audit Committee. We look forward to drawing on Greg's counsel and leadership as we build our corporate finance and operations infrastructure."

Since joining *PwC* in 1977, Greg has annually advised on nearly 50 domestic and international buy and sell side merger and acquisition transactions across a wide variety of industries. Greg also has considerable experience advising clients with initial public offerings and other filings with the *Securities and Exchange Commission*. Notable clients include *HGGC*, a private equity firm, and *Bain Capital*, where Greg led *PwC*'s involvement with some of *Bain*'s most significant transactions including, among others, *Domino's Pizza*, *Experian*, *Integrated Circuit Systems*, *DDI Corp.*, *Wesley Jessen VisionCare, Inc.*, and *HCA*. Among his many management responsibilities over the course of his tenure at *PwC*, Greg served as the Chairman of *PwC*'s US Partner Admissions Committee for three years. Greg is also the co-author of the book *From Term Sheets to Credit Agreements* and is a frequent speaker at financial industry conferences.

Greg currently serves as the Chairman of the Board of the *Francis Ouimet Scholarship Fund*, is a member of the Board of Trustees of *Loyola University Maryland* and was Chairman of the Board of the *Make-A-Wish Foundation of Massachusetts and Rhode Island*. A four-year student athlete and leader on the baseball team at *Boston College*, Greg has served in many fund-raising roles supporting *Boston College Athletics* and serves as a mentor to athletes at *Boston College*. He has been responsible for endowing two scholarship funds (*The Edward C. Pellegrini Scholarship* and *The Gailius Family Scholarship*) and in 2008 he received the prestigious *Edward C. Pellegrini Award* for distinguished service to the *Boston College Baseball Program*. Greg is a graduate of *Boston College - Wallace E. Carroll Graduate School of Management*.

About Advantagene, Inc.

Advantagene is a Massachusetts based biotechnology company developing its proprietary Gene Mediated Cytotoxic Immunotherapy (GMCI™) platform technology for the treatment of solid tumors. GMCI™ is an "off the shelf" low toxicity immunotherapy that stimulates a patient's immune system to generate a robust response against his or her individual cancer. The company is conducting clinical studies using its GMCI™ technology in lung, pancreas, prostate

and brain cancers with remarkable clinical results to date. Ongoing studies include a registration clinical trial with its lead candidate, ProstAtak[®], under a Special Protocol Assessment approved by the U.S. Food and Drug Administration, for the treatment of localized prostate cancer patients with intermediate to high risk disease choosing radiation therapy. If proven efficacious, ProstAtak[®] will be the first and only therapeutic pharmaceutical available for localized prostate cancer patients. For more information about Advantagene and our GMCI[™] cancer immunotherapy program please visit www.advantagene.com.

Contact

Media & Investor Relations

Advantagene, Inc.

440 Lexington Avenue

Auburndale, MA 02466

(617) 916-5445

info@advantagene.com

Released January 25, 2017